Patents by Inventor Georg Dahmann

Georg Dahmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11304929
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: April 19, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Weinstabl, Georg Dahmann, Matthias Treu, Bernd Wellenzohn, Stephan Karl Zahn
  • Publication number: 20220008386
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: March 18, 2018
    Publication date: January 13, 2022
    Inventors: Harald WEINSTABL, Georg DAHMANN, Matthias TREU, Bernd WELLENZOHN, Stephan Karl ZAHN
  • Publication number: 20210395267
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: September 1, 2021
    Publication date: December 23, 2021
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Annekatrin Charlotte HEIMANN, Uta Friederike LESSEL, Jens WILLWACHER
  • Patent number: 11174245
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dietrich Boese, Georg Dahmann, Harald Engelhardt, Mark Petronczki, Dirk Scharn
  • Patent number: 11136336
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: October 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Annekatrin Charlotte Heimann, Jens Willwacher
  • Patent number: 11001570
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: May 11, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Steurer, Georg Dahmann, Nina Kerres, Manfred Koegl
  • Publication number: 20210107919
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 15, 2021
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Annekatrin Charlotte HEIMANN, Uta Friederike LESSEL
  • Publication number: 20210107918
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 15, 2021
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Annekatrin Charlotte HEIMANN, Jens WILLWACHER
  • Patent number: 10947243
    Abstract: The invention relates to new substituted heteroaryls of formula 1 wherein A is selected from the group consisting of N and CH D is selected from the group consisting of CH, N, NH, S and O, E is selected from the group consisting of C and N, T is selected from the group consisting of C and N, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: March 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Georg Dahmann, Matthias Hoffmann, Jasna Klicic Badoux, David James Lamb, Clive McCarthy, Spencer Charles R. Napier, Karen Parrish, John Scott, Jennifer L. Swantek Fitzgerald, Edward Walker
  • Publication number: 20200377476
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: Dietrich BOESE, Georg DAHMANN, Harald ENGELHARDT, Mark PETRONCZKI, Dirk SCHARN
  • Patent number: 10849907
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 1, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Angelo Ceci, Georg Dahmann, Cornelia Dorner-Ciossek, Lothar Kussmaul, Roland Pfau, Dieter Wiedenmayer
  • Publication number: 20200330435
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 22, 2020
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Publication number: 20200071297
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 5, 2020
    Inventors: Steffen STEURER, Georg DAHMANN, Nina KERRES (Deceased), Manfred KOEGL
  • Publication number: 20190359620
    Abstract: The invention relates to new substituted heteroaryls of formula 1 wherein A is selected from the group consisting of N and CH D is selected from the group consisting of CH, N, NH, S and O, E is selected from the group consisting of C and N, T is selected from the group consisting of C and N, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Application
    Filed: August 8, 2019
    Publication date: November 28, 2019
    Inventors: Georg DAHMANN, Matthias HOFFMANN, Jasna KLICIC BADOUX, David James LAMB, Clive MCCARTHY, Spencer Charles R. NAPIER, Karen PARRISH, John SCOTT, Jennifer L. Swantek FITZGERALD, Edward WALKER
  • Publication number: 20190175605
    Abstract: The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Riccardo GIOVANNINI, Angelo CECI, Georg DAHMANN, Cornelia DORNER-CIOSSEK, Lothar KUSSMAUL, Roland PFAU, Dieter WIEDENMAYER
  • Publication number: 20190038600
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 7, 2019
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Patent number: 10154990
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Patent number: 10155751
    Abstract: The invention relates to new substituted heteroaryls of formula 1 or of formula 1? wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Georg Dahmann, Christian Gnamm, Daniel Robert Fandrick, John Scott, Clive McCarthy
  • Publication number: 20180148433
    Abstract: The invention relates to new substituted heteroaryls of formula 1 or of formula 1? wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 31, 2018
    Inventors: Matthias Hoffmann, Georg Dahmann, Christian Gnamm, Daniel Robert Fandrick, John Scott, Clive McCarthy
  • Publication number: 20180072744
    Abstract: The invention relates to new substituted heteroaryls of formula 1 wherein A is selected from the group consisting of N and CH D is selected from the group consisting of CH, N, NH, S and O, E is selected from the group consisting of C and N, T is selected from the group consisting of C and N, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R1, M and R3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 15, 2018
    Inventors: Georg DAHMANN, Matthias HOFFMANN, Jasna KLICIC, David James LAMB, Clive MCCARTHY, Spencer Charles R. NAPIER, Karen PARRISH, John SCOTT, Jennifer L. Swantek FITZGERALD, Edward WALKER